Results 121 to 130 of about 221,455 (333)
F1000Research, 2016 Rituximab is a monoclonal antibody that targets the CD20 B-cell-specific antigen and is widely used as therapy for B-cell lymphoma. Since rituximab depletes both malignant and normal B cells, it is increasingly being used to treat various conditions in ...
Albane Joly-Battaglini +8 more
doaj +1 more source
Example of tumor uptake on 89Zr-rituximab-PET, concordant with CD20 expression in biopsy.
, 2017 Axial images, from left to right attenuation corrected PET, low dose CT and fused PET/CT image of patient 3. a) 89Zr-rituximab-PET shows intense tumor uptake concordant with a CD20-positive biopsy (inguinal lymph node). b) Corresponding tumor location on
Guus A. M. S. van Dongen (506975) +7 more
core +1 more source
Immunosuppressive Drug Use in Limited Systemic Sclerosis: An International Survey
Arthritis Care &Research, EarlyView.Objective Current guidelines recommend immunosuppressive treatment for diffuse cutaneous systemic sclerosis but are less clear on their use in limited cutaneous systemic sclerosis (lcSSc) in the absence of internal organ complications. We conducted an international survey to understand current immunosuppressive drug prescribing patterns in lcSSc ...
Sabrina Hoa +3 more
wiley +1 more source
Role of rituximab in first-line treatment of chronic lymphocytic leukemia
, 2010 Jeffrey Bryan, Gautam BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAAbstract: Chronic lymphocytic leukemia (CLL) is a biologically heterogeneous illness that primarily afflicts the elderly.
null Bryan +2 more
core +1 more source
Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?
Arthritis Care &Research, EarlyView.Objective The objective is to describe and compare demographic, clinical, and serological characteristics of patients with systemic sclerosis (SSc) according to ethnic background. Methods Participants enrolled in the Canadian Scleroderma Research Group cohort who self‐identified to a single ethnicity group were included.
Danick Goulet +11 more
wiley +1 more source
Renal FailureObjective To explore the long-term efficacy and safety of the first single dose of rituximab in children with steroid-dependent minimal-change nephrotic syndrome (SD-MCNS) over a two-year period after infusion.Methods A 2-year retrospective observational
Xiao-Ling Niu +6 more
doaj +1 more source
Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease
EJNMMI Research, 2019 Background Orbital inflammatory diseases are a heterogenic group of conditions that often entail a difficult diagnostic process and many patients are treatment resistant.
Kamil G. Laban +3 more
doaj +1 more source
Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion
, 2008 The anti-CD20 mAb rituximab, first approved for use in B-cell malignancies, is increasingly used to treat a variety of autoimmune diseases. Two studies in this issue investigate the effects of rituximab in pemphigus.
Borradori, Luca, Zambruno, Giovanna
core +1 more source
Arthritis Care &Research, EarlyView.Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato +27 more
wiley +1 more source
Rituximab for the treatment of rheumatoid arthritis: an update
, 2013 Chi Chiu MokDepartment of Medicine, Tuen Mun Hospital, Hong Kong, Special Administrative Region of the People's Republic of ChinaAbstract: Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule expressed on the surface of B cells.
Mok CC
core